Business
Vor Bio Reports First Quarter 2022 Financial Results and Provides Company Update
Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022Data presented at Keystone Symposia demonstrates significant advancement
About this update from Vor Biopharma Inc.
[{"type":"text","content":"Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022Data presented at Keystone Symposia demonstrates significant advancement of novel multiplex editing platformIn-house manufacturing facility in Cambridge, MA operational in 2022 CAMBRIDGE, Mass., May 12, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2022, and provided a business update. “We remain fully focused on generating first-in-human clinical data from VBP101, our Phase 1/2a clinical trial of VOR33 in patients with relapsed/refractory AML, which will provide important proof of concept for our proprietary platform and has the potential to transform outcomes for patients with blood cancers,” said Dr. Robert Ang, Vor Bio’s President and Chief Executive Officer. “We also continue to make progress on our allogeneic healthy donor-derived CAR-T therapy VCAR33ALLO, which remains on track for IND submission in 1H 2023, and look forward to the opening of our new in-house eHSC and CAR-T clinical manufacturing facility later this year.” Corporate Highlights Data showcased at Keystone Symposia demonstrates success of several multiplex editing approaches. Data recently presented at the Keystone Symposia Precision Genome Engineering meeting, April 27-May 1, included two posters and a workshop discussion featuring data on multiplex gene editing in human hematopoietic stem cells using various genome editing technologies including base editing. The data show efficient removal of multiple surface antigens with high on-target editing and undetectable translocations, reinforcing the potential of Vor Bio’s novel platform and approach. Vor Bio’s in-house clinical manufacturing facility in Cambridge, MA headquarters on-track to become fully operational in 2022. The facility is designed to support clinical manufacturing for both Vor Bio’s eHSC and CAR-T product pipeline and will enable the Company to achieve flexible manufacturing capacity and reduce the time and cost required to manufacture cell therapy clinical candidates. The Company continues to make progress in manufacturing innovation with several recent and upcoming data presentations. A poster presentation at the International Society of Cell Therapy (ISCT), May 4-7, evaluated...